Oragenics, Inc. (NYSEAMERICAN:OGEN) Sees Significant Growth in Short Interest

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 792,779 shares, an increase of 39.0% from the February 26th total of 570,220 shares. Based on an average daily volume of 442,572 shares, the short-interest ratio is presently 1.8 days. Approximately 20.3% of the company’s stock are sold short.

Oragenics Price Performance

Shares of OGEN stock traded down $0.03 on Monday, reaching $0.50. 56,867 shares of the company were exchanged, compared to its average volume of 543,226. The company has a market cap of $2.19 million, a price-to-earnings ratio of -0.04 and a beta of 1.09. The company has a 50-day moving average of $0.78 and a 200-day moving average of $0.98. Oragenics has a one year low of $0.50 and a one year high of $9.60.

Institutional Investors Weigh In On Oragenics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Clear Street LLC acquired a new stake in shares of Oragenics in the 2nd quarter worth about $270,000. Bank of America Corp DE boosted its stake in Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after purchasing an additional 15,338 shares during the last quarter. Sabby Management LLC bought a new stake in Oragenics during the 3rd quarter worth approximately $77,000. DRW Securities LLC raised its stake in shares of Oragenics by 82.4% in the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after purchasing an additional 50,900 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Oragenics in the fourth quarter valued at approximately $26,000. 18.71% of the stock is owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.